ArticleYonsei medical journal2015
Characteristics and Survival of Breast Cancer Patients with Multiple Synchronous or Metachronous Primary Cancers.
Article in Yonsei medical journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 47 citations in OpenAlex.
- The risk and prognosis factors of second primary malignancies in hepatocellular carcinoma survivors.Discover oncology · 2026Article
- Gastric cancer and pleomorphic liposarcoma: A Case Report of synchronous dual primary malignancies.Frontiers in oncology · 2026Article
- Immunohistochemical expression of parathyroid hormone-related protein and ezrin in invasive breast carcinoma of no special type: a retrospective analysis.Diagnostic pathology · 2025Article
- Newer combination treatments for breast cancer coexisting with acute myeloid leukemia in the novel regimens era: A case report and literature review.Oncology letters · 2024Article
- Impact of immunohistochemical expression of kinesin family member 18A (Kif18A) and β-catenin in infiltrating breast carcinoma of no special type.World journal of surgical oncology · 2024Article
- Survival nomogram for patients withCancer pathogenesis and therapy · 2023Article
- Mammary nodules as incidental findings on chest computed tomography: a retrospective analysis on their frequency and predictive value.La Radiologia medica · 2023Article
- Risk and prognosis of secondary esophagus cancer after radiotherapy for breast cancer.Scientific reports · 2023Article
- Analysis of primary synchronous breast invasive ductal carcinoma and lung adenocarcinoma with next-generation sequencing: A case report.Oncology letters · 2023Article
- Neoadjuvant Immunotherapy Combined with Chemotherapy for Local Advanced Non-Small-Cell Lung Cancer in a Patient with a History of Breast Cancer: A Case Report.Current oncology (Toronto, Ont.) · 2022Article
- Common Multiple Primary Cancers Associated With Breast and Gynecologic Cancers and Their Risk Factors, Pathogenesis, Treatment and Prognosis: A Review.Frontiers in oncology · 2022Review
- Article
- Immunological significance of prognostic markers for breast cancer based on alternative splicing.American journal of translational research · 2022Article
- Case report: Quadruple primary malignant neoplasms including esophageal, ureteral, and lung in an elderly male.Open life sciences · 2022Article
- Nonmetastatic breast cancer patients subsequently developing second primary malignancy: A population-based study.Cancer medicine · 2021Article
- Genetic alterations associated with multiple primary malignancies.Cancer medicine · 2021Article
- Synchronous occurrence of breast cancer and refractory diffuse large B-cell abdominal lymphoma: Management and review of the literature.Intractable & rare diseases research · 2021Article
- Multiple primary malignant neoplasms: A case report and literature review.Oncology letters · 2019Article
- A rare case of cancer-to-cancer metastasis: breast cancer to renal cell cancer : Case report and review of literature.Wiener medizinische Wochenschrift (1946) · 2019Review
- Survival and chemotherapy-related risk of second primary malignancy in breast cancer patients: a SEER-based study.International journal of clinical oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeNewly developed extra-mammary multiple primary cancers (MPCs) are an issue of concern when considering the management of breast cancer survivors. This study aimed to investigate the prevalence of MPCs and to evaluate the implications of MPCs on the survival of breast cancer patients. MATERIALS AND
methodsA total of 8204 patients who underwent surgery at Severance Hospital between 1990 and 2012 were retrospectively selected. Clinicopathologic features and survival over follow-up periods of ≤5 and >5 years were investigated using univariate and multivariate analyses.
resultsDuring a mean follow-up of 67.3 months, 962 MPCs in 858 patients (10.5%) were detected. Synchronous and metachronous MPCs were identified in 23.8% and 79.0% of patients, respectively. Thyroid cancer was the most prevalent, and the second most common was gynecologic cancer. At ≤5 years, patients with MPCs were older and demonstrated significantly worse survival despite a higher proportion of patients with lower-stage MPCs. Nevertheless, an increased risk of death in patients with MPCs did not reach statistical significance at >5 years. The causes of death in many of the patients with MPCs were not related to breast cancer. Stage-matched analysis revealed that the implications of MPCs on survival were more evident in the early stages of breast disease.
conclusionBreast cancer patients with MPCs showed worse survival, especially when early-stage disease was identified. Therefore, it is necessary to follow screening programs in breast cancer survivors and to establish guidelines for improving prognosis and quality of life.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.